- Home
- JMM vs INMB Comparison
JMM vs INMB Comparison
Compare JMM & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMM
- INMB
- Stock Information
- Founded
- JMM 1988
- INMB 2015
- Country
- JMM United States
- INMB United States
- Employees
- JMM N/A
- INMB N/A
- Industry
- JMM Trusts Except Educational Religious and Charitable
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- JMM Finance
- INMB Health Care
- Exchange
- JMM Nasdaq
- INMB Nasdaq
- Market Cap
- JMM 58.6M
- INMB 68.9M
- IPO Year
- JMM N/A
- INMB 2019
- Fundamental
- Price
- JMM $6.43
- INMB $2.31
- Analyst Decision
- JMM
- INMB Buy
- Analyst Count
- JMM 0
- INMB 4
- Target Price
- JMM N/A
- INMB $9.53
- AVG Volume (30 Days)
- JMM 16.1K
- INMB 6.9M
- Earning Date
- JMM 01-01-0001
- INMB 07-31-2025
- Dividend Yield
- JMM 5.44%
- INMB N/A
- EPS Growth
- JMM N/A
- INMB N/A
- EPS
- JMM N/A
- INMB N/A
- Revenue
- JMM N/A
- INMB $50,000.00
- Revenue This Year
- JMM N/A
- INMB $82.14
- Revenue Next Year
- JMM N/A
- INMB $28,750.98
- P/E Ratio
- JMM N/A
- INMB N/A
- Revenue Growth
- JMM N/A
- INMB N/A
- 52 Week Low
- JMM $5.29
- INMB $1.89
- 52 Week High
- JMM $6.10
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- JMM 65.15
- INMB 26.84
- Support Level
- JMM $6.22
- INMB $2.22
- Resistance Level
- JMM $6.41
- INMB $2.49
- Average True Range (ATR)
- JMM 0.11
- INMB 0.94
- MACD
- JMM 0.01
- INMB -0.24
- Stochastic Oscillator
- JMM 100.00
- INMB 4.31
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.